Higgins Paul G, Wisplinghoff Hilmar, Stefanik Danuta, Seifert Harald
Institute for Medical Microbiology, Immunology, and Hygiene, University of Cologne, 50935 Cologne, Germany.
Antimicrob Agents Chemother. 2004 May;48(5):1586-92. doi: 10.1128/AAC.48.5.1586-1592.2004.
Acinetobacter baumannii is an important nosocomial pathogen usually in the context of serious underlying disease. Multidrug resistance in these organisms is frequent. The beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam have intrinsic activity against Acinetobacter strains. To evaluate their potential therapeutic usefulness, we determined the in vitro activity of ampicillin, sulbactam, ampicillin-sulbactam, cefoperazone, cefoperazone-sulbactam, piperacillin, piperacillin-sulbactam, tazobactam, piperacillin-tazobactam, amoxicillin, clavulanic acid, amoxicillin-clavulanic acid, ticarcillin, and ticarcillin-clavulanic acid against multidrug-resistant A. baumannii. All isolates were epidemiologically characterized by RAPD [random(ly) amplified polymorphic DNA] analysis and/or pulsed-field gel electrophoresis and represented different strain types, including sporadic strains, as well as outbreak-related strains. The MICs were determined by agar dilution on Mueller-Hinton agar (using fixed concentrations, as well as fixed ratios for beta-lactamase inhibitors) and the E-test. The majority of E-test results were within two dilutions of those recorded by agar dilution, with the exception of piperacillin-tazobactam. Sulbactam was superior to clavulanic acid and tazobactam and may represent an alternative treatment option for infections due to multiresistant A. baumannii strains. beta-Lactamase inhibitors have intrinsic activity but do not enhance activity of beta-lactams against A. baumannii. Testing with the inhibitor added at a fixed concentration as recommended for piperacillin-tazobactam and ticarcillin-clavulanic acid by the National Committee for Clinical Laboratory Standards may falsely suggest high activity or gives uninterpretable results due to trailing. If combinations are used for testing, fixed ratios may give more useful results.
鲍曼不动杆菌是一种重要的医院病原体,通常存在于患有严重基础疾病的情况下。这些细菌中多药耐药很常见。β-内酰胺酶抑制剂克拉维酸、舒巴坦和他唑巴坦对不动杆菌菌株具有内在活性。为了评估它们潜在的治疗用途,我们测定了氨苄西林、舒巴坦、氨苄西林-舒巴坦、头孢哌酮、头孢哌酮-舒巴坦、哌拉西林、哌拉西林-舒巴坦、他唑巴坦、哌拉西林-他唑巴坦、阿莫西林、克拉维酸、阿莫西林-克拉维酸、替卡西林和替卡西林-克拉维酸对多重耐药鲍曼不动杆菌的体外活性。所有分离株均通过RAPD[随机(ly)扩增的多态性DNA]分析和/或脉冲场凝胶电泳进行流行病学特征分析,代表不同的菌株类型,包括散发病株以及与暴发相关的菌株。MIC通过在Mueller-Hinton琼脂上进行琼脂稀释法测定(使用固定浓度以及β-内酰胺酶抑制剂的固定比例)和E-test法。除哌拉西林-他唑巴坦外,大多数E-test结果在琼脂稀释法记录结果的两个稀释度范围内。舒巴坦优于克拉维酸和他唑巴坦,可能是多重耐药鲍曼不动杆菌菌株所致感染的一种替代治疗选择。β-内酰胺酶抑制剂具有内在活性,但不会增强β-内酰胺类药物对鲍曼不动杆菌的活性。按照美国国家临床实验室标准委员会对哌拉西林-他唑巴坦和替卡西林-克拉维酸的建议,以固定浓度添加抑制剂进行检测可能会错误地显示高活性,或者由于拖尾而得出无法解释的结果。如果使用联合制剂进行检测,固定比例可能会得出更有用的结果。